8-K: Tenax Therapeutics CMO Stuart Rich Shifts to Part-Time Role

Tenax Therapeutics' Chief Medical Officer, Dr. Stuart Rich, will transition to a four-day work week with a prorated salary, effective January 1, 2026.

Summary

• Tenax Therapeutics, Inc. and its Chief Medical Officer, Dr. Stuart Rich, entered into a second amendment to his Executive Employment Agreement on January 6, 2026.
• The amendment, approved by the Board on December 22, 2025, modifies Dr. Rich's work schedule.
• Effective January 1, 2026, Dr. Rich will devote an average of four days per week (80%) to his duties as Chief Medical Officer.
• His annual base salary will be prorated to reflect this modified work schedule.
• Dr. Rich is permitted to engage in personal investments, reasonable volunteer services, serve on the board of charitable organizations, and serve on the board of one non-competing publicly traded company.
• Dr. Rich acknowledged and voluntarily consented to the amendment, confirming it does not constitute a breach of his employment agreement or grounds for termination for 'Good Reason'.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a reduction in a key executive's work hours could be perceived negatively, the filing frames it as a mutually agreed-upon amendment, suggesting a structured approach to executive retention and compensation. It does not indicate immediate positive or negative operational impacts.

Positives

• The company retains its Chief Medical Officer, Dr. Stuart Rich, albeit on a modified schedule, which can be beneficial for continuity.
• The agreement allows Dr. Rich flexibility while maintaining his role, potentially aiding in executive retention.

Negatives

• Dr. Rich's reduced work schedule to four days per week (80%) may decrease his direct availability and time commitment to the company's operations.

Future Outlook

The filing primarily details a change in an executive's employment terms and does not provide specific forward-looking statements or guidance regarding company performance or strategic direction beyond the effective date of the employment amendment.

Management Comments

• Dr. Rich will faithfully perform all duties normally associated with the position of Chief Medical Officer, including additional duties reasonably prescribed by the CEO.
• Dr. Rich consents to this Amendment, acknowledging and agreeing that his consent and acceptance are both knowing and voluntary.
• Dr. Rich further acknowledges and agrees that this Amendment will not constitute or create a breach of any material provision of the Employment Agreement or any grounds for him to terminate his employment for Good Reason.

Industry Context

In the biotechnology and pharmaceutical sectors, retaining experienced Chief Medical Officers is crucial for clinical development and regulatory strategy. Companies sometimes offer flexible work arrangements to retain key talent, balancing executive needs with corporate demands. This move could be seen as a strategy to maintain Dr. Rich's expertise while potentially managing operational costs or accommodating his personal commitments.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: May view the reduced work schedule of a key executive with mixed feelings; potentially positive for cost management or executive retention, but potentially negative if it signals reduced strategic focus or availability.
• Employees: No direct impact mentioned, but could set a precedent for flexible work arrangements for senior staff.
• Customers/Suppliers: No direct impact is immediately apparent from this administrative change.

Key Dates

Keywords

Tenax Therapeutics, Stuart Rich, Chief Medical Officer, Employment Agreement, Executive Compensation, Corporate Governance, Biotechnology, Pharmaceuticals